
Rainer Rupprecht

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10216485/publications.pdf Version: 2024-02-01



PAINED RUDDDECHT

#	Article	IF	CITATIONS
1	Neuroinflammation and psychiatric disorders: Relevance of C1q, translocator protein (18 kDa) (TSPO), and neurosteroids. World Journal of Biological Psychiatry, 2022, 23, 257-263.	2.6	9
2	Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. Brain Sciences, 2022, 12, 204.	2.3	2
3	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. Cancers, 2022, 14, 53.	3.7	12
4	Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO). Nature Neuroscience, 2022, 25, 317-329.	14.8	29
5	Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?. Molecular Psychiatry, 2022, 27, 2918-2926.	7.9	21
6	Bifrontal high-frequency transcranial random noise stimulation is not effective as an add-on treatment in depression. Journal of Psychiatric Research, 2021, 132, 116-122.	3.1	9
7	In Vivo Assessment of Neuroinflammation in <scp>4â€Repeat</scp> Tauopathies. Movement Disorders, 2021, 36, 883-894.	3.9	37
8	Dissociation of endocrine responses to the Trier Social Stress Test in Virtual Reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18ÂkDa (TSPO) ligand etifoxine. Psychoneuroendocrinology, 2021, 124, 105100.	2.7	5
9	Supracategorical fear information revealed by aversively conditioning multiple categories. Cognitive Neuroscience, 2021, 12, 28-39.	1.4	4
10	The cytokine ILâ€17A as a marker of treatment resistance in major depressive disorder?. European Journal of Neuroscience, 2021, 53, 172-182.	2.6	24
11	A direct comparison of neuronavigated and non-neuronavigated intermittent theta burst stimulation in the treatment of depression. Brain Stimulation, 2021, 14, 335-343.	1.6	23
12	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
13	C1q, a small molecule with high impact on brain development: putative role for aging processes and the occurrence of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 809-812.	3.2	13
14	Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	6.4	2
15	Computer-Assisted Avatar-Based Treatment for Dysfunctional Beliefs in Depressive Inpatients: A Pilot Study. Frontiers in Psychiatry, 2021, 12, 608997.	2.6	5
16	Meta-analysis of brain structural changes after electroconvulsive therapy in depression. Brain Stimulation, 2021, 14, 927-937.	1.6	25
17	Cognitive behavioral treatment for insomnia is equally effective in insomnia patients with objective short and normal sleep duration. Sleep Medicine, 2020, 66, 271-275.	1.6	22
18	TSPO PET With 18F-GE-180 to Differentiate Variants of Multiple Sclerosis. Clinical Nuclear Medicine, 2020, 45, e447-e448.	1.3	5

#	Article	IF	CITATIONS
19	SARS-CoV-2 Risk Management in Clinical Psychiatry: A Few Considerations on How to Deal With an Unrivaled Threat. Frontiers in Psychiatry, 2020, 11, 550.	2.6	12
20	Psychopharmacology- is there still room for progress in these days?. World Journal of Biological Psychiatry, 2020, 21, 239-240.	2.6	0
21	CDF15 promotes simultaneous astrocyte remodeling and tight junction strengthening at the blood–brain barrier. Journal of Neuroscience Research, 2020, 98, 1433-1456.	2.9	16
22	Major Depressive Disorder is Associated with Impaired Mitochondrial Function in Skin Fibroblasts. Cells, 2020, 9, 884.	4.1	28
23	Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2887-2900.	6.4	10
24	Linking Personality Traits to Individual Differences in Affective Spaces. Frontiers in Psychology, 2020, 11, 448.	2.1	7
25	Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment. NeuroImmunoModulation, 2020, 27, 152-162.	1.8	13
26	Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET. Clinical Nuclear Medicine, 2020, 45, 992-993.	1.3	2
27	A view behind the mask of sanity: meta-analysis of aberrant brain activity in psychopaths. Molecular Psychiatry, 2019, 24, 463-470.	7.9	76
28	CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. International Journal of Molecular Sciences, 2019, 20, 3359.	4.1	45
29	Copeptin in CCK-4-induced panic in healthy man: Sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms. Psychoneuroendocrinology, 2019, 110, 104433.	2.7	2
30	Daily high-frequency transcranial random noise stimulation of bilateral temporal cortex in chronic tinnitus – a pilot study. Scientific Reports, 2019, 9, 12274.	3.3	16
31	Microglial Pro-Inflammatory and Anti-Inflammatory Phenotypes Are Modulated by Translocator Protein Activation. International Journal of Molecular Sciences, 2019, 20, 4467.	4.1	54
32	The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. International Journal of Molecular Sciences, 2019, 20, 2283.	4.1	94
33	Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells. Psychoneuroendocrinology, 2019, 106, 65-76.	2.7	57
34	The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia. Journal of Neuroinflammation, 2019, 16, 43.	7.2	35
35	Relating experimentally-induced fear to pre-existing phobic fear in the human brain. Social Cognitive and Affective Neuroscience, 2018, 13, 164-172.	3.0	12
36	Neurobiology of depression: A neurodevelopmental approach. World Journal of Biological Psychiatry, 2018, 19, 349-359.	2.6	59

#	Article	IF	CITATIONS
37	Brain stimulationâ€induced neuroplasticity underlying therapeutic response in phantom sounds. Human Brain Mapping, 2018, 39, 554-562.	3.6	19
38	The neural representation of an individualized relational affective space. Neuropsychologia, 2018, 120, 35-42.	1.6	12
39	False Belief Reasoning in Adults with and without Autistic Spectrum Disorder: Similarities and Differences. Frontiers in Psychology, 2018, 9, 183.	2.1	15
40	Classical Risk Factors and Inflammatory Biomarkers: One of the Missing Biological Links between Cardiovascular Disease and Major Depressive Disorder. International Journal of Molecular Sciences, 2018, 19, 1740.	4.1	40
41	Effects of genetic variants in the TSPO gene on protein structure and stability. PLoS ONE, 2018, 13, e0195627.	2.5	19
42	A Pilot Study of Peripheral Muscle Magnetic Stimulation as Add-on Treatment to Repetitive Transcranial Magnetic Stimulation in Chronic Tinnitus. Frontiers in Neuroscience, 2018, 12, 68.	2.8	8
43	Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-CE-180. Clinical Nuclear Medicine, 2018, 43, 518-519.	1.3	18
44	An fMRI study on the comparison of different types of false belief reasoning: False belief-based emotion and behavior attribution. Social Neuroscience, 2017, 12, 1-13.	1.3	4
45	Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool. Sleep Medicine Reviews, 2017, 32, 95-108.	8.5	58
46	Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC). European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 751-766.	3.2	44
47	Extracellular Signal–Regulated Kinases: A Role for Mood Disorders and the Emotional Component of Pain?. Biological Psychiatry, 2017, 81, 639-641.	1.3	3
48	Macrophage-Derived Chemokine: A Putative Marker of Pharmacological Therapy Response in Major Depression?. NeuroImmunoModulation, 2017, 24, 106-112.	1.8	17
49	The rTPJ's overarching cognitive function in networks for attention and theory of mind. Social Cognitive and Affective Neuroscience, 2017, 12, 157-168.	3.0	56
50	TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Research, 2017, 7, 89.	2.5	55
51	"l Am I and My Bacterial Circumstancesâ€ŧ Linking Gut Microbiome, Neurodevelopment, and Depression. Frontiers in Psychiatry, 2017, 8, 153.	2.6	61
52	Individualized Repetitive Transcranial Magnetic Stimulation Treatment in Chronic Tinnitus?. Frontiers in Neurology, 2017, 8, 126.	2.4	30
53	Fluoxetine Requires the Endfeet Protein Aquaporin-4 to Enhance Plasticity of Astrocyte Processes. Frontiers in Cellular Neuroscience, 2016, 10, 8.	3.7	55
54	Imbalance in subregional connectivity of the right temporoparietal junction in major depression. Human Brain Mapping, 2016, 37, 2931-2942.	3.6	16

#	Article	IF	CITATIONS
55	Triple-site rTMS for the treatment of chronic tinnitus: a randomized controlled trial. Scientific Reports, 2016, 6, 22302.	3.3	34
56	The neural basis of sex differences in sexual behavior: A quantitative meta-analysis. Frontiers in Neuroendocrinology, 2016, 43, 28-43.	5.2	53
57	Combined rTMS treatment targeting the Anterior Cingulate and the Temporal Cortex for the Treatment of Chronic Tinnitus. Scientific Reports, 2016, 5, 18028.	3.3	35
58	A neural circuit encoding sexual preference in humans. Neuroscience and Biobehavioral Reviews, 2016, 68, 530-536.	6.1	37
59	Desipramine targets astrocytes to attenuate synaptic plasticity via modulation of the ephrinA3/EphA4 signalling. Neuropharmacology, 2016, 105, 154-163.	4.1	11
60	The effect of partial sleep deprivation on computer-based measures of fitness to drive. Sleep and Breathing, 2016, 20, 285-292.	1.7	17
61	Severe chronic insomnia is not associated with higher body mass index. Journal of Sleep Research, 2015, 24, 514-517.	3.2	23
62	Sexual motivation is reflected by stimulus-dependent motor cortex excitability. Social Cognitive and Affective Neuroscience, 2015, 10, 1061-1065.	3.0	9
63	The ACDC Pilot Trial: Targeting the Anterior Cingulate by Double Cone Coil rTMS for the Treatment of Depression. Brain Stimulation, 2015, 8, 240-246.	1.6	51
64	New perspectives in neurosteroid action: open questions for future research. Frontiers in Cellular Neuroscience, 2014, 8, 268.	3.7	5
65	Structural Brain Changes Following Left Temporal Low-Frequency rTMS in Patients with Subjective Tinnitus. Neural Plasticity, 2014, 2014, 1-10.	2.2	17
66	Amygdalohippocampal neuroplastic changes following neuroleptic treatment with quetiapine in first-episode schizophrenia. International Journal of Neuropsychopharmacology, 2014, 17, 833-843.	2.1	9
67	Translocator protein (18ÂkDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. Journal of Neuroinflammation, 2014, 11, 3.	7.2	177
68	Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic–pituitary–adrenal-axis activity in relation to antidepressant effectiveness. Journal of Psychiatric Research, 2014, 52, 15-20.	3.1	15
69	The role of allopregnanolone in depression and anxiety. Progress in Neurobiology, 2014, 113, 79-87.	5.7	227
70	Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology, 2014, 39, 141-151.	2.7	35
71	Antipsychotic treatment with quetiapine increases the cortical silent period. Schizophrenia Research, 2014, 156, 128-132.	2.0	17
72	Feasibility, Safety and Efficacy of Transcutaneous Vagus Nerve Stimulation in Chronic Tinnitus: An Open Pilot Study. Brain Stimulation, 2014, 7, 740-747.	1.6	75

#	Article	IF	CITATIONS
73	The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic–pituitary–adrenal-axis activity: A randomized trial. Journal of Psychiatric Research, 2014, 53, 76-83.	3.1	45
74	Translocator protein (18ÂkDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 107-112.	3.2	49
75	Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews Drug Discovery, 2010, 9, 971-988.	46.4	774
76	A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression. Archives of General Psychiatry, 2009, 66, 966.	12.3	284
77	Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. Science, 2009, 325, 490-493.	12.6	299
78	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. World Journal of Biological Psychiatry, 2008, 9, 248-312.	2.6	661
79	GABA _A receptors as targets for novel anxiolytic drugs. World Journal of Biological Psychiatry, 2006, 7, 231-237.	2.6	26
80	Induced Panic Attacks Shift γ-Aminobutyric Acid Type A Receptor Modulatory Neuroactive Steroid Composition in Patients With Panic Disorder. Archives of General Psychiatry, 2003, 60, 161.	12.3	131
81	The Influence of Subchronic Administration of the Neurosteroid Allopregnanolone on Sleep in the Rat. Neuropsychopharmacology, 2001, 25, 576-584.	5.4	46
82	Vigabatrin Decreases Cholecystokinin-Tetrapeptide (CCK-4) Induced Panic in Healthy Volunteers. Neuropsychopharmacology, 2001, 25, 699-703.	5.4	59
83	Attenuation of HPA Axis Hyperactivity and Simultaneous Clinical Deterioration in a Depressed Patient treated with Mirtazapine. World Journal of Biological Psychiatry, 2001, 2, 103-105.	2.6	7
84	Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1610-1615.	3.6	13
85	Pharmacological Characterisation of Cortical γ-Aminobutyric Acid Type A (GABA _A) Receptors in Two Wistar Rat Lines Selectively Bred for High and Low Anxiety-Related Behaviour. World Journal of Biological Psychiatry, 2000, 1, 137-143.	2.6	12
86	Effects of Fluoxetine, Indomethacine and Placebo on 3α, 5α Tetrahydroprogesterone (THP) Plasma Levels in Uncomplicated Alcohol Withdrawal. World Journal of Biological Psychiatry, 2000, 1, 101-104.	2.6	26
87	Assessment of neuroleptic-like properties of progesterone. Psychopharmacology, 1999, 143, 29-38.	3.1	60
88	Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends in Neurosciences, 1999, 22, 410-416.	8.6	605
89	Sleep Endocrine Effects of Megestrol Acetate in Healthy Men. Journal of Neuroendocrinology, 1998, 10, 719-727.	2.6	7
90	Effects of Antidepressant Treatment on Neuroactive Steroids in Major Depression. American Journal of Psychiatry, 1998, 155, 910-913.	7.2	432

6